Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: A randomized study in healthy subjects

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 353-363

  Kubitza, Dagmar ^a   Becka, Michael ^a   Mück, Wolfgang ^a   Krätzschmar, Jöern ^a  

^a Clinical Sciences Bayer HealthCare   (Germany)

Author keywords

international normalized ratio; pharmacodynamics; prothrombin time; rivaroxaban; therapy transition; warfarin

Indexed keywords

ALANINE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PHYTOMENADIONE; PLACEBO; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; FACTOR IIA; MORPHOLINE DERIVATIVE; PROTHROMBIN; THIOPHENE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PLASMA CONCENTRATION-TIME CURVE; PREMEDICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STEADY STATE; TANDEM MASS SPECTROMETRY; THROMBOPLASTIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR VIIA; FACTOR XA; HEALTHY VOLUNTEERS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MORPHOLINES; PROTHROMBIN; PROTHROMBIN TIME; RIVAROXABAN; THIOPHENES; WARFARIN; YOUNG ADULT;

EID: 84904888759     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12349     Document Type: Article

References (22)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S-198.
2. Eriksson BI, Quinlan DJ, Weitz JI,. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
3. Kamal AH, Tefferi A, Pruthi RK,. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007; 82: 864-873.
4. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G,. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
5. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG,. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
6. Barrett YC, Wang Z, Frost C, Shenker A,. Clinical laboratory measurement of direct Factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
7. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE,. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
8. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W,. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
9. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S,. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
10. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG,. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
11. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD,. RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
12. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
13. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
15. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM,. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
16. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G,. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-e88S.
17. Rohde G,. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
18. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 454S-545S.
19. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GYH, Manning WJ, American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 546S-592.
20. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL,. Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
21. Schulman S, Crowther MA,. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
22. van den Besselaar AM, Fogar P, Pengo V, Palareti G, Braham S, Moia M, Tripodi A,. Biological variation of INR in stable patients on long-term anticoagulation with warfarin. Thromb Res 2012; 130: 535-537.